AstraZeneca: lupus drug meets goal in late-stage study
(CercleFinance.com) - AstraZeneca said that its experimental human monoclonal antibody anifrolumab has met the primary endpoint of a Phase III trial evaluating response in lupus patients.
In the study, which enrolled 373 patients for one year, the treatment for systemic lupus erythematosus (SLE) achieved a statistically-significant and clinically-meaningful reduction in disease activity versus placebo, the drugmaker said.
Systemic lupus erythematosus is a debilitating auto-immune disease, for which only one new treatment has been approved in the last 60 years.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In the study, which enrolled 373 patients for one year, the treatment for systemic lupus erythematosus (SLE) achieved a statistically-significant and clinically-meaningful reduction in disease activity versus placebo, the drugmaker said.
Systemic lupus erythematosus is a debilitating auto-immune disease, for which only one new treatment has been approved in the last 60 years.
Copyright (c) 2019 CercleFinance.com. All rights reserved.